# The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

- **DOI:** [10.3390/nu12082296](https://doi.org/10.3390/nu12082296)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** A competent PRISMA-registered synthesis finding curcumin a promising mesalamine adjunct in ulcerative colitis, constrained by a small heterogeneous evidence base with no quantitative pooling or certainty grading.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-15
- **Evaluation page:** https://www.nabu.science/paper/10.3390%2Fnu12082296

## Strengths

- **Transparent, registered, reproducible review protocol** The review is PROSPERO-registered, declares PRISMA compliance, and provides database-specific search strings with dual independent screening, supporting transparency and reproducibility.
  - Dimension: methodological rigour
  - Location: Methods 2.1-2.2; Table 1
- **Clear tabulation of trial evidence** A detailed summary table lays out each included trial's population, intervention, dose, duration, outcome measures, and headline results, making the evidence base easy to inspect.
  - Dimension: reporting
  - Location: Table 2
- **Appropriately hedged, clinically relevant conclusions** The review consistently frames curcumin as a possible adjunct rather than a proven therapy and explicitly declines to extend conclusions to Crohn's disease in the absence of low-bias trials.
  - Dimension: contribution
  - Location: Abstract; Discussion final paragraphs

## Limitations

- **Quality threshold used to exclude eligible trials** Eligible trials were removed after risk-of-bias and Jadad scoring rather than retained and interpreted with quality-sensitivity, which narrows the evidence base in a non-standard way and can shift the conclusions the review reaches.
  - Dimension: methodological rigour
  - Location: Methods 2.3, 2.5; Results 3.1-3.2; Figure 1
- **No certainty grading or quantitative synthesis** The review performs no GRADE or equivalent certainty assessment and no meta-analysis, and offers no explicit justification for omitting pooling, limiting its ability to quantify effects or support strength-of-evidence claims for a 2020 clinical review.
  - Dimension: methodological rigour
  - Location: Methods and Results overall; Discussion
- **Conclusions reach beyond sparse heterogeneous evidence** Efficacy-leaning language appears despite only six small trials with heterogeneous formulations, doses, and routes and one clearly negative trial, and an unexplained set of additional records appears in the flow diagram.
  - Dimension: positioning
  - Location: Abstract; Figure 1; Discussion final paragraphs

## Reliability checks

Caveats (3 of 4 checks).

- **Internal coherence:** Noted. Eligible trials were excluded after risk-of-bias/Jadad assessment rather than retained and interpreted with quality-sensitivity, which alters the evidence base feeding the conclusions. The PRISMA flow diagram reports 57 additional records from unspecified sources not described in the Methods, and some conclusion language implies efficacy beyond what six small, heterogeneous RCTs with one negative trial support.
- **Research conduct:** Clean. PROSPERO registration (CRD42019104827) and PRISMA use are declared and conflicts of interest are declared as none; no ethics approval is required for a review of published literature. Absence of a data-availability statement or shared extraction dataset is a transparency limitation but not a conduct concern.
- **Reference integrity:** Pending

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
